Market Closed -
Nasdaq
02:00:00 04/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.9529
USD
|
+0.28%
|
|
+5.89%
|
-1.00%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
124.6
|
302.5
|
558.5
|
163.8
|
85.56
|
85.41
|
-
|
-
|
Enterprise Value (EV)
1 |
124.6
|
302.5
|
558.5
|
163.8
|
85.56
|
85.41
|
85.41
|
85.41
|
P/E ratio
|
-1
x
|
-6.9
x
|
-3.15
x
|
0.96
x
|
-1.03
x
|
-1.03
x
|
-0.94
x
|
-1.29
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.95
x
|
56.3
x
|
282
x
|
4.84
x
|
264
x
|
9.18
x
|
34.2
x
|
2.31
x
|
EV / Revenue
|
9.95
x
|
56.3
x
|
282
x
|
4.84
x
|
264
x
|
9.18
x
|
34.2
x
|
2.31
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-5.56
x
|
-3.49
x
|
-
|
-0.99
x
|
-0.96
x
|
-1.14
x
|
FCF Yield
|
-
|
-
|
-18%
|
-28.7%
|
-
|
-101%
|
-104%
|
-87.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
61,382
|
62,634
|
86,862
|
88,045
|
88,891
|
89,630
|
-
|
-
|
Reference price
2 |
2.030
|
4.830
|
6.430
|
1.860
|
0.9625
|
0.9529
|
0.9529
|
0.9529
|
Announcement Date
|
25/02/20
|
25/02/21
|
01/03/22
|
02/03/23
|
29/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
12.52
|
5.372
|
1.979
|
33.82
|
0.324
|
9.305
|
2.5
|
37.03
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-116
|
-44.52
|
-90.51
|
-60.39
|
-93.06
|
-89.47
|
-102.8
|
-81.88
|
Operating Margin
|
-926.46%
|
-828.67%
|
-4,573.52%
|
-178.53%
|
-28,723.77%
|
-961.49%
|
-4,110.87%
|
-221.13%
|
Earnings before Tax (EBT)
1 |
-112.6
|
-43.52
|
-173.2
|
172.2
|
-82.1
|
-82.37
|
-97.13
|
-77.39
|
Net income
1 |
-112.6
|
-43.52
|
-173.2
|
172.2
|
-82.1
|
-83.07
|
-97.13
|
-74.71
|
Net margin
|
-899.24%
|
-810.16%
|
-8,753.71%
|
509.01%
|
-25,337.96%
|
-892.7%
|
-3,885.31%
|
-201.76%
|
EPS
2 |
-2.030
|
-0.7000
|
-2.040
|
1.940
|
-0.9300
|
-0.9267
|
-1.017
|
-0.7371
|
Free Cash Flow
1 |
-
|
-
|
-100.4
|
-46.94
|
-
|
-86
|
-89
|
-75
|
FCF margin
|
-
|
-
|
-5,075.19%
|
-138.77%
|
-
|
-924.23%
|
-3,560%
|
-202.55%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/02/20
|
25/02/21
|
01/03/22
|
02/03/23
|
29/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.107
|
0.046
|
0.015
|
0.44
|
32.56
|
0.814
|
0.283
|
0.026
|
0.011
|
0.004
|
0.06
|
0.06
|
0.06
|
6.06
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-18.6
|
-39.53
|
-24.77
|
-23.45
|
11.65
|
-23.81
|
-24.22
|
-21.35
|
-26.69
|
-20.81
|
-24.39
|
-23.7
|
-24.15
|
-17.03
|
-
|
Operating Margin
|
-17,383.18%
|
-85,939.13%
|
-1,65,140%
|
-5,328.86%
|
35.77%
|
-2,925.55%
|
-8,557.6%
|
-82,107.69%
|
-2,42,627.27%
|
-5,20,250%
|
-36,273.62%
|
-39,504.77%
|
-40,243.57%
|
-281.01%
|
-
|
Earnings before Tax (EBT)
1 |
-18.56
|
-39.5
|
-24.77
|
-23.47
|
241.5
|
-21.08
|
-21.37
|
-18.58
|
-23.99
|
-18.16
|
-21.87
|
-21.58
|
-22.12
|
-15.47
|
-
|
Net income
1 |
-18.56
|
-39.5
|
-24.77
|
-23.47
|
241.4
|
-20.96
|
-21.37
|
-18.58
|
-23.99
|
-18.16
|
-21.87
|
-21.58
|
-22.12
|
-15.47
|
-
|
Net margin
|
-17,345.79%
|
-85,865.22%
|
-1,65,113.33%
|
-5,333.64%
|
741.4%
|
-2,574.94%
|
-7,551.94%
|
-71,446.15%
|
-2,18,054.55%
|
-4,54,025%
|
-31,916.12%
|
-35,962.15%
|
-36,868.57%
|
-255.21%
|
-
|
EPS
2 |
-0.2100
|
-0.4500
|
-0.2800
|
-0.2700
|
2.750
|
-0.2400
|
-0.2400
|
-0.2100
|
-0.2700
|
-0.2000
|
-0.2500
|
-0.2357
|
-0.2457
|
-0.1729
|
-0.2300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/11/21
|
01/03/22
|
16/05/22
|
08/08/22
|
03/11/22
|
02/03/23
|
04/05/23
|
03/08/23
|
02/11/23
|
29/02/24
|
01/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-100
|
-46.9
|
-
|
-86
|
-89
|
-75
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.16
|
0.06
|
0.21
|
0.07
|
-
|
0.06
|
0.05
|
0.05
|
Capex / Sales
|
1.26%
|
1.08%
|
10.46%
|
0.21%
|
-
|
0.61%
|
2%
|
0.14%
|
Announcement Date
|
25/02/20
|
25/02/21
|
01/03/22
|
02/03/23
|
29/02/24
|
-
|
-
|
-
|
Last Close Price
0.9529
USD Average target price
7
USD Spread / Average Target +634.60% Consensus |
1st Jan change
|
Capi.
|
---|
| -1.00% | 85.41M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +38.61% | 12.63B | | +313.59% | 8.49B |
Bio Therapeutic Drugs
|